医学
自发性细菌性腹膜炎
白蛋白
加药
腹膜炎
内科学
肌酐
急性肾损伤
肝硬化
回顾性队列研究
血清白蛋白
养生
胃肠病学
外科
作者
Lily Huang,Ann C. Marcotte,Taryn Murray,Jared Barkes,Alissa Clayton
标识
DOI:10.1177/10600280251318012
摘要
Background: Albumin is recommended in the management of patients with spontaneous bacterial peritonitis (SBP) to reduce rates of renal injury and mortality. Current guideline recommendations suggest an intravenous albumin dosing regimen of 1.5 g/kg on day 1 and 1 g/kg on day 3, although a maximum dosing strategy is not well-defined. Objective: The purpose of this study was to evaluate differences in renal injury for patients with SBP treated with a capped dose less than or equal to 100 g vs a weight-based dose greater than 100 g. Methods: A retrospective analysis was conducted at a single academic medical center for patients with a diagnosis of cirrhosis treated with albumin for SBP. The primary outcome examined rates of acute renal injury at 5 days between patients treated with capped dose vs weight-based doses of intravenous albumin. Secondary outcomes included resolution of SBP by day 5, death by day 5, death by day 30, and change in serum creatinine from day 0 to day 5. Results: In total, 258 patient encounters were analyzed, with 154 included in this study. There were 70 encounters encompassing the capped dose and 84 in the non-capped. Acute renal injury at day 5 was observed in 10% (n = 7) of the capped dosed group and 6% (n = 5) of the non-capped group ( P = 0.381). Conclusion and Relevance: This study did not show a significant difference in outcomes associated with a capped albumin dose at 100 g for SBP. Application of these data may aid in reducing health system and patient costs.
科研通智能强力驱动
Strongly Powered by AbleSci AI